Skip to main content

Ingrid A. Beattie, PhD

Member

[email protected]

+1.617.348.1838

Share:

Ingrid is an intellectual property lawyer who handles patent prosecution and related matters for a broad range of biotechnology clients. She works extensively with universities, including inventors and engineers in academia and helps them patent their innovations and discoveries. Her practice spans the fields of immunology, microbiology, molecular biology, cardiovascular medicine, oncology, ophthalmology, clinical diagnostics, and medical devices. Ingrid also counsels clients on strategic issues, including patent portfolio management and licensing options. She draws on her previous experience as a technology transfer associate at a Boston-area cancer treatment institute.

Ingrid’s practice emphasizes patent prosecution in the area of biotechnology, particularly in the fields of molecular biology, immunology, microbiology, cardiovascular medicine, clinical diagnostics, and medical devices, and includes advising clients on issues relating to patent portfolio management and licensing. She has been a frequent speaker at Biotechnology Industry Organization and Association of University Technology Managers conferences.

Prior to joining Mintz, Ingrid was a technology transfer associate at the Dana-Farber Cancer Institute, and then practiced at another prominent Boston law firm.

Education

  • Suffolk University Law School (JD)
  • Emory University (PhD, Immunology and Microbiology )
  • Fairfield University (BS, Biology)

Recognition & Awards

  • Included on the Massachusetts Super Lawyers: Rising Star: Intellectual Property list (2005 – 2007)

Involvement

  • Past president, Boston Patent Law Association
  • Member, Licensing Executives Society
  • Member, Association of University Technology Managers
  • Member, Town of Milton Conservation Commission

Viewpoints

U.S. patent law elevates the importance of “the inventor” to an extent unseen in the rest of the world.  Unlike many other countries, ownership of patent applications in the United States initially vests in the inventors listed on the application.
Authorship is the currency of academia, and principle investigators are often generous with technicians and collaborators when listing authors on a paper.  However, the identification of an “inventor” has legal significance in the U.S. and cannot be applied to those who have not made an inventive contribution. 
We’ll start with the first question a patent attorney might ask you: Have you told anyone about your invention?

Events

Moderator
Mar
12
2017

AUTM 2017 Annual Meeting

Association of University Technology Managers

The Diplomat Beach Resort Hollywood, Florida